Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
-
Skincare Division Achieves New Sales Milestone, Enters Holiday Season with Strong Momentum
-
Strategic Restructuring Efforts Contributes to Achieving Record Monthly Sales and Sets Stage for Positive Projections for Year-End Growth
- 护肤部门取得了新的销售里程碑,以强劲的势头进入假日季节
- 战略重组工作有助于实现创纪录的月度销售,为年底增长做好积极准备
NEWPORT BEACH, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) ("Elevai", "Elevai Labs" or the "Company"), a diversified holding company, announces that its wholly owned subsidiary, Elevai Skincare Inc. ("Elevai Skincare"), has achieved a record-breaking month in sales for 2024, marking a significant milestone for the Company. This achievement underscores the success of transformational restructuring efforts led by Elevai Labs' new executive team and the adoption of a performance-driven culture.
加州纽波特比奇,2024年12月4日(环球新闻社)—Elevai实验室股份有限公司(纳斯达克股票代码:ELAB)(“Elevai”、“Elevai实验室”或“公司”),一家多元化控股公司,宣布其全资子公司Elevai护肤公司(“Elevai护肤”)在2024年实现了销售的创纪录月份,为公司标志性的里程碑。该成就突显了Elevai实验室新执行团队领导的变革性重组努力以及公司采用的以绩效为导向的文化的成功。
The milestone comes as the Elevai Skincare division heads into the holiday season with strong momentum, strengthened by strategic initiatives that have streamlined operations, enhanced productivity, and positioned the brand for continued growth. Elevai's management expressed its appreciation for the hard work and dedication of the Elevai Skincare operations team and sales force, who have demonstrated resilience in adapting to the newly implemented performance-based culture.
Elevai护肤部门在强劲势头下步入假日季节,得益于重新调整运营、提升生产力和为品牌持续增长而定位的战略举措。Elevai管理层对Elevai护肤运营团队和销售团队的辛勤工作和奉献表示赞赏,他们在适应新实施的基于绩效的文化方面表现出了韧性。
Since taking leadership of Elevai Labs, the parent company of Elevai Skincare, in the third quarter of 2024, the new management team has prioritized operational efficiency, strategic sales growth, and a high-performance sales culture. These efforts culminated in the highest monthly revenue figures for Elevai Skincare in 2024, exceeding the previous four months average sales by 65%, paving the way for strong year-end performance. The new management team's focus on cost management and strategic initiatives has delivered higher revenue while reducing operating expenses, reaffirming their commitment to operational improvements with a desire to reach positive net profits.
自2024年第三季度接管Elevai实验室(Elevai护肤的母公司)以来,新管理团队已将操作效率、战略销售增长和高绩效销售文化作为优先任务。这些努力导致Elevai护肤部门在2024年创造了最高的月度营业收入,比前四个月的平均销售额提高了65%,为年底表现奠定了坚实基础。新管理团队专注于成本管理和战略举措,并在减少营业费用的同时提高了营业收入,再次确认他们致力于运营改进并渴望实现正面净利润。
Key drivers of success include:
成功的关键驱动因素包括:
- Sales Culture Transformation: Performance-based incentives and a results-oriented environment have driven motivation and accountability across the sales team.
- Optimized Budgets and Marketing Strategies: Stringent budgeting and accountability measures have ensured efficient resource allocation. By prioritizing impactful campaigns, the sales team has strengthened relationships with core physician-dispensed channels and driven disciplined, sustainable growth.
- Integrated Marketing and Sales Objectives: Improved collaboration between marketing and sales teams has aligned campaigns with sales goals, enhancing lead generation and conversion outcomes.
- Targeted Training Programs: Comprehensive training programs for both the sales team and physician-dispensed customers have bolstered advanced product knowledge, improved patient recommendation strategies, and strengthened clinic partnerships.
- 销售文化转型: 基于绩效的激励和以结果为导向的环境推动了销售团队的积极性和责任感。
- 优化预算和营销策略: 严格的预算和责任措施确保了资源的有效配置。通过优先考虑有影响力的活动,销售团队加强了与核心医生配送渠道的关系,并推动了有纪律的、可持续的增长。
- 整合营销和销售目标: 营销和销售团队之间的合作加强,使活动与销售目标保持一致,提升了线索生成和转化结果。
- 针对性培训计划: 针对销售团队和医生配送客户的全面培训计划增强了产品的专业知识,改善了患者推荐策略,加强了诊所伙伴关系。
Preliminary unaudited sales data for Elevai Skincare for November 2024 reflects revenue of $300K significantly higher than monthly figures earlier in the year:
Elevai Skincare 2024年11月的初步未经审计的销售数据显示,营业收入达30万美元,明显高于当年较早月份的数据:
- July: $160K
- August: $199K
- September: $168K
- October: $198K
- 七月:160K美元
- 八月:199K美元
- 九月:168K美元
- 十月:198K美元
Positioned for Continued Growth
Elevai Skincare's strong performance aligns with the Company's overarching goal of creating shareholder value through operational excellence and strategic growth across its subsidiaries. With strong momentum entering the holiday season, the Company is well-positioned to drive further success as it closes out the year.
为持续增长而定位
Elevai护肤品的强劲表现与公司通过运营卓越和战略增长在旗下子公司中创造股东价值的总体目标一致。随着强劲的势头进入假期季节,公司定位良好,有望在年底取得更大成功。
About Elevai Labs, Inc.
关于Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit .
Elevai实验室公司(纳斯达克股票代码:ELAB)专注于医疗美学和生物制药药物的研发,致力于皮肤美学和与肥胖及代谢健康相关的治疗创新。该公司在医疗美学和生物制药领域拥有三家全资子公司的多样化组合,分别为Elevai护肤公司,Elevai生命科学公司和Elevai研究公司。更多信息请访问。
About Elevai Skincare Inc.
关于Elevai护肤品公司。
A subsidiary of Elevai, Elevai Skincare is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focuses on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology. For more information, please visit elevaiskincare.com.
Elevai的子公司Elevai护肤品是一家医疗美容公司,专注于开发和商业化尖端医生配方的皮肤和头发护理产品,侧重于基于科学的医生配方市场,利用尖端技术重新定义护肤和头发护理,包括其电芯外泌体技术。欲了解更多信息,请访问elevaiskincare.com。
Forward-Looking Statements
前瞻性声明
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新闻稿中包含的关于非历史事实的表述属于根据1995年修订后的《私人证券诉讼改革法》(Private Securities Litigation Reform Act of 1995)属于“前瞻性声明”。诸如“相信”、“预期”、“计划”、“潜力”、“将会”和“未来”或类似表达,如“期待”等,旨在识别前瞻性声明。前瞻性声明的表述截至本新闻稿日期,并非历史事实也非保证未来业绩。相反,它们仅基于我们当前对业务未来、未来计划和策略、预测、预期事件和趋势、经济状况、监管机构活动和未来监管法规以及其他未来状况的信仰、预期和假设。由于前瞻性声明涉及未来,因此存在固有的不确定性、风险和难以预测以及许多超出我们控制范围的环境变化。尽管公司认为这些前瞻性声明中表达的期望是合理的,但公司无法保证这些期望会被证明是正确的,公司警告投资者实际结果可能与预期结果大不相同。因此,您不应该依赖任何这些前瞻性声明。这些风险和不确定因素包括但不限于: Elevai有限的营运历史和历史亏损; Elevai筹集额外资金以完成产品候选品的开发和任何商业化能力; Elevai依赖于其产品候选品EL-22和EL-32的成功;Elevai可能在启动、招募或完成任何临床试验方面出现延迟;来自正在为相似用途开发产品的第三方的竞争; Elevai获取、维护和保护其知识产权的能力;Elevai在制造、临床试验和临床前研究方面依赖第三方;以及 Elevai对其增长、策略、进展和研究的设计、目标和时间的期望。这些以及其他风险在Elevai提交给美国证券交易委员会(“SEC”)的文件中有更详尽描述,其中包括截至2023年12月31日的年度十-K表格中于2024年3月29日向SEC提交的公司年度报告中的“风险因素”部分,以及随后提交给或向SEC提供的其他文件。敦促投资者和持股人免费阅读这些文件,网址为www.sec.gov。本新闻稿中包含的所有前瞻性声明仅适用于其发布日期。除非法律要求,公司不承诺更新这些表述以反映形成声明的日期之后发生的事件或现有的情况。
IR Contact:
IR@ElevaiLabs.com
IR联系方式:
IR@ElevaiLabs.com
译文内容由第三方软件翻译。